The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

Wee J. Chng, Esteban D Braggio, George Mulligan, Barbara Bryant, Ellen McPhail, Riccardo Valdez, Ahmet Dogan, Rafael Fonseca

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

Centrosome amplification is common in myeloma and may be involved in disease pathogenesis. We have previously derived a gene expression-based centrosome index (CI) that correlated with centrosome amplification and was an independent prognostic factor in a small cohort of heterogeneously treated patients. In this study, we validated the prognostic significance of the CI in 2 large cohorts of patients entered into clinical trials and showed that a high CI is a powerful independent prognostic factor in both newly diagnosed and relapsed patients, whether treated by intensive therapy (total therapy II) or novel agents (bortezomib). Tumors with high CI overexpressed genes coding for proteins involved in cell cycle, proliferation, DNA damage, and G2-M checkpoints, and associated with the centrosome and kinetochore/microtubules. In particular, aurora kinases are significantly overexpressed in patients with high CI, with concordant increase in protein expression. Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis.

Original languageEnglish (US)
Pages (from-to)1603-1609
Number of pages7
JournalBlood
Volume111
Issue number3
DOIs
StatePublished - 2008

Fingerprint

Aurora Kinases
Centrosome
Amplification
Cells
Gene expression
Tumors
Proteins
Genes
DNA
Kinetochores
Therapeutics
Microtubules
DNA Damage
Cell Cycle
Cell Proliferation
Clinical Trials

ASJC Scopus subject areas

  • Hematology

Cite this

The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. / Chng, Wee J.; Braggio, Esteban D; Mulligan, George; Bryant, Barbara; McPhail, Ellen; Valdez, Riccardo; Dogan, Ahmet; Fonseca, Rafael.

In: Blood, Vol. 111, No. 3, 2008, p. 1603-1609.

Research output: Contribution to journalArticle

@article{0debd59371f0497cbc18a3a3def05bff,
title = "The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition",
abstract = "Centrosome amplification is common in myeloma and may be involved in disease pathogenesis. We have previously derived a gene expression-based centrosome index (CI) that correlated with centrosome amplification and was an independent prognostic factor in a small cohort of heterogeneously treated patients. In this study, we validated the prognostic significance of the CI in 2 large cohorts of patients entered into clinical trials and showed that a high CI is a powerful independent prognostic factor in both newly diagnosed and relapsed patients, whether treated by intensive therapy (total therapy II) or novel agents (bortezomib). Tumors with high CI overexpressed genes coding for proteins involved in cell cycle, proliferation, DNA damage, and G2-M checkpoints, and associated with the centrosome and kinetochore/microtubules. In particular, aurora kinases are significantly overexpressed in patients with high CI, with concordant increase in protein expression. Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis.",
author = "Chng, {Wee J.} and Braggio, {Esteban D} and George Mulligan and Barbara Bryant and Ellen McPhail and Riccardo Valdez and Ahmet Dogan and Rafael Fonseca",
year = "2008",
doi = "10.1182/blood-2007-06-097774",
language = "English (US)",
volume = "111",
pages = "1603--1609",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "3",

}

TY - JOUR

T1 - The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition

AU - Chng, Wee J.

AU - Braggio, Esteban D

AU - Mulligan, George

AU - Bryant, Barbara

AU - McPhail, Ellen

AU - Valdez, Riccardo

AU - Dogan, Ahmet

AU - Fonseca, Rafael

PY - 2008

Y1 - 2008

N2 - Centrosome amplification is common in myeloma and may be involved in disease pathogenesis. We have previously derived a gene expression-based centrosome index (CI) that correlated with centrosome amplification and was an independent prognostic factor in a small cohort of heterogeneously treated patients. In this study, we validated the prognostic significance of the CI in 2 large cohorts of patients entered into clinical trials and showed that a high CI is a powerful independent prognostic factor in both newly diagnosed and relapsed patients, whether treated by intensive therapy (total therapy II) or novel agents (bortezomib). Tumors with high CI overexpressed genes coding for proteins involved in cell cycle, proliferation, DNA damage, and G2-M checkpoints, and associated with the centrosome and kinetochore/microtubules. In particular, aurora kinases are significantly overexpressed in patients with high CI, with concordant increase in protein expression. Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis.

AB - Centrosome amplification is common in myeloma and may be involved in disease pathogenesis. We have previously derived a gene expression-based centrosome index (CI) that correlated with centrosome amplification and was an independent prognostic factor in a small cohort of heterogeneously treated patients. In this study, we validated the prognostic significance of the CI in 2 large cohorts of patients entered into clinical trials and showed that a high CI is a powerful independent prognostic factor in both newly diagnosed and relapsed patients, whether treated by intensive therapy (total therapy II) or novel agents (bortezomib). Tumors with high CI overexpressed genes coding for proteins involved in cell cycle, proliferation, DNA damage, and G2-M checkpoints, and associated with the centrosome and kinetochore/microtubules. In particular, aurora kinases are significantly overexpressed in patients with high CI, with concordant increase in protein expression. Human myeloma cell lines with higher CI are more responsive to treatment with a novel aurora kinase inhibitor. Aurora kinase may represent novel therapeutic targets in these patients with very poor prognosis.

UR - http://www.scopus.com/inward/record.url?scp=38949203768&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38949203768&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-06-097774

DO - 10.1182/blood-2007-06-097774

M3 - Article

VL - 111

SP - 1603

EP - 1609

JO - Blood

JF - Blood

SN - 0006-4971

IS - 3

ER -